Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 11/20 | 0.45 |
| ▸ | REN | P00797 | 4/20 | 0.45 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437158 | 0.92 | ACE (0.43) | ACERENGRB2KDM4EF2 | |
| SCHEMBL30671935 | 0.89 | GRB2 (0.44) | ACEGRB2 | |
| SCHEMBL29590258 | 0.88 | NAA50 (0.41) | ACERENGRB2ACE2 | |
| SCHEMBL30437074 | 0.88 | EPHA2 (0.41) | ACERENGRB2KDM4EF2 | |
| SCHEMBL29411971 | 0.86 | OPRK1 (0.46) | ACEGRB2 | |
| SCHEMBL29994788 | 0.86 | OPRK1 (0.46) | ACEGRB2 | |
| SCHEMBL30069169 | 0.84 | ACE (0.62) | ACERENKDM4EF2LMNA | |
| SCHEMBL31487371 | 0.83 | GRB2 (0.53) | GRB2 | |
| SCHEMBL30692365 | 0.83 | ACE (0.51) | ACERENKDM4EF2LMNA | |
| SCHEMBL30052416 | 0.82 | ACE (0.47) | ACERENGRB2KDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | claimed |
| WO-2023202654-A1 | COMPOUND AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-10-26 | — | — | WO | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023202654-A1 | COMPOUND AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | ACE 2388/4885REN 1463/4885GRB2 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.